Related Experiment Video
Updated: Mar 24, 2026
07:48
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
Published on: January 7, 2019
7.4K
A new cyclic RGD peptide dimer for integrin αvβ3 imaging.
1Department of Nuclear Medicine, Peking University First Hospital, Beijing, China. china__doctor@163.com.
European Review for Medical and Pharmacological Sciences
|March 10, 2016
Summary
A new Arg-Gly-Asp (RGD) peptide, 131I-c(RGD)2, was developed to target integrin αvβ3. This radiolabeled peptide shows high specificity and effectively visualizes αvβ3-positive tumors in preclinical models.
Area of Science:
- Biomedical Engineering
- Radiochemistry
- Molecular Imaging
Background:
- Integrin αvβ3 is a key biomarker overexpressed in various tumors.
- Targeted molecular imaging agents are crucial for accurate tumor detection and characterization.
Purpose of the Study:
- To design and synthesize a novel Arg-Gly-Asp (RGD) peptide dimer.
- To evaluate the diagnostic potential of Iodine-131 labeled cyclic RGD dimer [131I-c(RGD)2] for imaging αvβ3-positive tumors.
Main Methods:
- Peptide design using V-life software and synthesis of a cyclic RGD dimer [c(RGD)2].
- Radiolabeling of c(RGD)2 with Iodine-131 (131I) using the chloramine-T method.
- In vitro binding affinity (Kd) assessment with U87 MG glioma cells and in vivo imaging and biodistribution studies in tumor-bearing mice.
Main Results:
- The synthesized 131I-c(RGD)2 molecule demonstrated high stability and hydrophilicity.
- High binding affinity (Kd = 3.87 × 10^-9 M) and specificity for αvβ3 on U87 MG cells.
- Clear visualization of αvβ3-positive tumors with favorable tumor-to-normal tissue ratios observed in vivo.
Conclusions:
- The developed 131I-c(RGD)2 molecule exhibits excellent properties for αvβ3-targeted imaging.
- This radiotracer holds significant promise for the non-invasive detection and monitoring of αvβ3-expressing tumors.
